From VistaPartners two days ago in their newsletter. To access it, you go to their site and register for free:
"Soligenix, Inc. (SNGX)
Current Price: $1.94 Target Price: $7.00
• On June 23rd, Soligenix announced that it will be working with the National Organization for Rare Disorders (NORD) and the Cutaneous Lymphoma Foundation (CLF) to educate and recruit patients for its pivotal Phase 3 clinical study of SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). SGX301 has previously been granted both orphan drug and fast track designations from the US Food and Drug Administration (FDA) for the first-line treatment of CTCL, a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system. NORD, the leading, independent nonprofit organization committed to the identification, treatment and cures of rare diseases, and CLF, an independent, nonprofit patient advocacy organization whose mission is to support patients with cutaneous lymphoma, will assist the Company in educating patients and raising awareness of the Phase 3 clinical trial among patients who are eligible for participation.
• The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date, the Company has been awarded approximately $40 million mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $58 million in active government contract and grant funding still available to support its associated research programs through 2018.
• Soligenix has an exclusive worldwide collaboration deal with Intrexon Corporation (~$4.3B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Soligenix also has an exclusive commercial collaboration with SciClone Pharmaceuticals (~$455M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis, a potentially billion dollar market."
